Form 4 for AORT ARTIVION, INC.

Accepted 2023-03-01 00:00:00 ET · period of report 2023-02-23 · accession 0000784199-23-000044 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2023-03-01	2023-02-23	AORT	Stanton Marshall S.	SVP, Clinical, MD Affair	A - Grant	$0.00	+11.2K	50.5K	+29%	$0
M	2023-03-01	2023-02-27	AORT	Stanton Marshall S.	SVP, Clinical, MD Affair	S - Sale	$12.94	-2,337	49.3K	-5%	-$30.2K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-02-23	A	A	3,770	$0.00	44,218	D	—	—	(F1) Represents performance stock units granted on Feb 23, 2022. Hundred percent (100%) were issued on Feb 23, 2023.
2	Common	Common Stock	2023-02-27	S	D	1,176	$12.94	43,042	D	—	—	(F2) These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.
3	Common	Common Stock	2023-02-23	A	A	7,440	$0.00	50,482	D	—	—	(F3) Represents performance stock units granted on Feb 23, 2022. Fifty percent (50%) were issued on Feb 23, 2023. The remaining shares earned in connection with the Feb 2022 grant will be eligible to vest and be issued as follows: 25% on 02/23/2024, and 25% on 02/23/2025, assuming continued employment on the relevant vesting date.
4	Common	Common Stock	2023-02-27	S	D	1,161	$12.94	49,321	D	—	—	(F2) These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.